Posthaemorrhagic ventricular dilatation in the premature infant: natural history and predictors of outcome


Objective: To investigate the natural history and predictors of outcome of posthaemorrhagic ventriculomegaly in the very low birthweight (VLBW) infant.

Methods: All VLBW infants admitted between September 1994 and September 1997 to the neonatal intensive care units of Brigham and Women’s Hospital (Boston), Children’s Hospital (Boston), and Christchurch Women’s Hospital (New Zealand) with germinal matrix intraventricular haemorrhage (IVH) were identified. All charts and ultrasound scans were reviewed to define the natural history and perinatal and/or postnatal factors of value in prediction of the course of posthaemorrhagic ventriculomegaly. Progressive ventricular dilatation (PVD) was defined from the results of serial cranial ultrasound scans.

Results: A total of 248 VLBW infants had evidence of IVH (22% of all VLBW infants, mean (SD) gestational age 26.8 (2.6) weeks). A quarter of the infants exhibited PVD. Spontaneous arrest of PVD occurred without treatment in 38% of infants with PVD. Of the remaining 62% with persistent PVD, 48% received non-surgical treatment only (pharmacological and/or drainage of cerebrospinal fluid by serial lumbar punctures). 34% received surgical treatment with insertion of a ventriculoperitoneal reservoir and/or shunt, and 18% died. The development of PVD after IVH and adverse short term outcome, such as the requirement for surgery, were predicted most strongly by the severity of IVH.

Conclusions: These data reflect the natural history of PVD in the 1990s and show that, despite a slight reduction in its overall incidence, there appears to be a more aggressive course, with appreciable mortality and morbidity in the extremely premature infant. The major predictor of adverse short term outcome, defined as death or need for surgical intervention, was the severity of IVH. These findings may be valuable for the management of very small premature infants.

Improvements in perinatal and neonatal care have contributed to a reduction in the overall incidence of intraventricular haemorrhage (IVH) in very low birthweight (VLBW, birthweight < 1500 g) premature infants from 40–50% in the later 1970s and 1980s to 20–25% in the 1990s. However, the 1990s have also seen increased survival of the extremely premature infant (birthweight < 750 g), who is at greatest risk of severe IVH and subsequent progressive posthaemorrhagic ventricular dilatation (PVD). The morbidity of PVD is appreciable. Up to 90% of infants have subsequent neuromotor disability, 76% exhibit pronounced disability, and 56% have multiple impairments. Studies of the natural history of PVD in the late 1980s suggested that about one third of infants with IVH develop PVD. Of VLBW infants with PVD, 85% subsequently had arrest of progression, spontaneous or induced by non-surgical intervention, and 15% required ventriculoperitoneal (VP) shunts for control of raised intracranial pressure. With an increased proportion of extremely preterm infants now surviving, the aim of this study was to define the incidence and natural history of PVD in VLBW infants in the 1990s and to define predictive factors for adverse outcome.

METHODS

Subjects
All VLBW infants with IVH admitted between September 1994 and September 1997 to the newborn intensive care units at Brigham and Women’s Hospital and Children’s Hospital in Boston and Christchurch Women’s Hospital in New Zealand were identified. Diagnostic coding of IVH on neonatal discharge summaries was cross referenced with radiology records of all infants in each unit with a diagnosis of IVH on any cranial ultrasound report during the study interval. Cases identified were cross referenced against all infants with a birth weight of 1500 g or less admitted to each intensive care unit to ensure the validity of the cohort sample. Infants with chromosomal abnormality, congenital heart disease (patent ductus arteriosus excepted), and identified congenital abnormality of the central nervous system were excluded from the study. The mean (SD) gestational age of our cohort was 26.8 (2.6) weeks with a mean (SD) birth weight of 950 (306) g. The institutional research review boards approved this study in all the participating centres.

Data collection
Case records were reviewed independently by two neonatologists (BPM and TEI). Basic information, gestational age, birth weight, and perinatal factors were recorded. A CRIB score, a physiological measure of stability based on blood pressure, oxygen requirement, gestational age, birth weight, and presence of congenital abnormality in the first 12 hours of life, was calculated for each infant. Postnatal variables including measures of physiological derangement in the first 48 hours’ and outcome were collected.

Cranial ultrasound scans
In these units, cranial ultrasound scans were carried out routinely on all infants of birth weight > 1500 g. The scans were
performed during the first five days of life and then in the sec-
ond and sixth weeks of life. If any abnormality was identified,
they were carried out on at least a weekly basis. For this study,
in each site, every scan on each infant was re-evaluated by an 
experienced radiologist (VR, GAT, and NJA) blinded to the in-
fant’s perinatal details, to confirm the reported ultrasono-
graphic findings and to quantify the ventricular dilatation.

Cranial ultrasound scans were carried out via the anterior 
fountanelle in standard coronal and parasagittal views. IVH 
was classified as grades 1 to 4 according to Volpe’s clas-
sification. Grade 1 represents germinal matrix haemor-
rhage only with no obvious IVH. Grade 2 represents IVH occu-
pying 10–50% of ventricular area on parasagittal view. Grade 3 
is IVH with haemorrhage occupying > 50% of ventricular area 
on parasagittal view. Grade 4 represents severe IVH with asso-
ciated periventricular echodensity. Ventricular enlargement 
was qualitatively classified as mild, moderate, or severe for the 
lateral, third, and fourth ventricles on each ultrasound scan. 
Quantitative measurements of ventricular enlargement were 
recorded on each successive cranial ultrasound scan on each 
infant in the following standardised manner. The width of the 
anterior horn of the lateral ventricles was measured in a coro-
nal view, with the plane of the scan at the level of the foramina 
of Monro (just anterior to the choroid plexus in the third ven-
tricle). The width was measured on each side as the distance 
between the medial wall and the floor of the lateral ventricle 
at the widest point. The reference range for this dimension in 
healthy preterm infants of 23–33 weeks gestation has been 
defined as 0–2.9 mm. Periventricular white matter injury was 
classified by a modified grading system as either localised 
(frontal, parietal, or parieto-occipital) or extensive (frontal to 
parieto-occipital) echodensity or echolucency.

The population with posthaemorrhagic ventricular dilat-
ation was defined as those infants with IVH whose ventricles 
were dilated at any stage on cranial ultrasound scan 
relative to the haemorrhage identified on the initial 
cranial ultrasound scan. Mild ventricular dilatation was 
defined qualitatively by fullness in the lateral ventricles with 
rounding of the anterior frontal horns. The median quantita-
tive anterior horn width for mild ventricular dilatation was 6 
mm (range 4–10). Moderate ventricular dilatation was defined 
qualitatively as dilatation in the lateral ventricular system 
with ventricular effacement and loss or reduction of the sub-
archnoid space. The median quantitative anterior horn width 
for moderate ventricular dilatation was 14 mm (range 8–18). 
Marked ventricular dilatation was defined as dilatation 
including the lateral ventricular, third, and fourth ventricles 
with more pronounced ventricular effacement and loss of the 
subarchnoid space. The median quantitative anterior horn 
width for marked ventricular dilatation was 22 mm (range 
12–36). PVD was defined by either a rapid severe increase in 
lateral ventricle size on cranial ultrasound within seven days 
of IVH or the continued progression of ventricular dilatation 
identified on cranial ultrasound for more than 14 days after 
IVH characterised by a change in qualitative classification 
(from mild to moderate or severe ventricular dilatation) or 
quantitatively by an increase in anterior horn width of at least 
6 mm. The median maximal anterior horn width for infants 
with PVD was 15 mm (range 8–36).

Treatments
Non-surgical treatment was defined as pharmacological 
interventions (acetazolamide and/or furosemide) and serial 
lumbar punctures to remove cerebrospinal fluid for the treat-
ment of PVD (this did not include diagnostic taps performed 
for diagnosis of sepsis). Surgical treatments for PVD were 
either (a) ventriculostomy with placement of a ventricular 
catheter and subcutaneous reservoir for continuous 
intermittent ventricular drainage, or (b) VP shunt. Timing of all 
treatments, medical or surgical, and all complications of 
treatments was recorded.

Statistical analysis
Statistical analyses were performed with SYSTAT and SPSS for 
Windows (SPSS Inc, Chicago, Illinois, USA). The infants with 
IVH surviving beyond 14 days of life were classified into three 
groups on the basis of the severity of ventricular dilatation: no 
ventricular dilatation, ventricular dilatation without progres-
sion, and PVD. For comparison of the measures of perinatal 
status between the three groups, tests of significance were 
based on the χ² test of independence for dichotomous 
measures and one way analysis of variance for continuous 
measures. To examine the factors that predicted outcome 
severity, the data were analysed using an ordinal logistic 
regression model in which the three level outcome severity 
indexes were regressed on potential predictors in two stages, 
first regressing the outcome on predictors other than grade of 
IVH and then including grade of IVH. The characteristics of 
the 19 infants who had surgical intervention for IVH were 
compared with those of the remaining 202 infants, using the 
χ² test of independence for dichotomous measures and one 
way analysis of variance for continuous measures. As 
discussed below, only two variables were significantly related 
to the likelihood of surgery—that is, grade of IVH 
(p < 0.0001) and inotropic support (p < 0.005)—and these 
variables were entered into a logistic regression model to pre-
dict the risk of surgery.

RESULTS

IVH
A total of 248 VLBW infants had evidence of IVH. The overall 
incidence of all grades of IVH among VLBW admissions to the 
three units in aggregate was 22%. Severe IVH (grade 3/IV) 
accounted for 32% of all IVH. The mean (SD) gestational age 
of the infants with severe IVH was 26.0 (1.9) weeks. Of note, 
82% of cases with grade 3 IVH were bilateral.

Mortality
Fifty four infants (22%) died, with half of the deaths occurring 
in the first 14 days of life. Two thirds of all deaths in the first 
14 days (60% of all deaths) occurred in infants with severe 
IVH (grade 3/IV) (table 1).

Ventricular dilatation
A total of 221 VLBW Infants with IVH survived beyond 14 days 
and thus were eligible for analysis of the presence of ventricu-
lar dilatation. Of these 221 infants, 112 (51%) showed no ven-
tricular dilatation at any stage (fig 1A). The remaining 109 
infants (49%) showed ventricular dilatation on at least one 
cranial ultrasound scan after the IVH. Fifty three infants 
(24%) showed no significant change in ventriculomegaly 
qualitatively or quantitatively. The median anterior horn 
width was 6 mm (range 4–9). These infants were classified as 
having non-progressive ventricular dilatation (fig 1). Fifty six 
in infants (25%) developed PVD on serial cranial ultrasound 
scans after IVH (fig 1A). Of particular note, 45 of these 56 
infants (80%) had severe (grade 3/4) IVH.

Treatment for PVD
Of the 56 infants with PVD, 21 infants (38%) did not receive 
any treatment and had spontaneous arrest and/or resolution 
of their PVD (fig 1B). The remaining 35 infants (62% of PVD) 
had persistent PVD. Six of these infants died before receiving 
treatment for PVD, with death resulting principally from vari-
ous systemic complications of prematurity. Thus, 29 infants 
were treated for persistent PVD. In all but two, management 
was non-surgical—that is, pharmacological agents (acetazola-
mide and/or diuretics) or serial lumbar punctures or both. 
Thus 20 infants received combined pharmacological treat-
ment and serial lumbar punctures, and six infants received 
lumbar punctures alone with no accompanying pharmacological 
treatment, one infant had pharmacological treatment with no
serial lumbar punctures, and only two infants had VP shunt insertion with neither prior pharmacological treatment nor serial lumbar punctures. Pharmacological treatment for PVD began on median day of life 12 (range 6–22), whereas serial lumbar punctures started on median day of life 19 (range 11–36) with a median number of 11 serial lumbar punctures (range 3–33) undertaken. Of the 27 infants with persistent PVD treated pharmacologically or with serial lumbar punctures or both, 17 (63%) ultimately required a VP shunt for continued progression, eight experienced arrest of progression, and two died from systemic complications of prematurity (fig 1B). Overall, 29 infants (52% of PVD) had spontaneous or non-surgical treatment induced arrest, and 19 infants (34% of PVD) required surgical intervention with a ventricular reservoir or VP shunt (fig 1B).

Surgical intervention was carried out on median day of life 35 (range 5–147) in a total of 19 infants (34% of PVD). Twelve infants had a ventricular reservoir inserted as the initial procedure, and seven had VP shunt insertion as their first surgical procedure. One infant died soon after ventricular reservoir insertion, and 10 of the surviving 11 infants ultimately required a VP shunt. Consistent with their principal role as a temporary measure, reservoirs were inserted earlier—that is, on median day of life 24—than the initial placement of the VP shunt on median day of life 50.

Thus, of the 109 infants with ventricular dilatation, 82 (75%) either did not exhibit progression (49%) or experienced arrest of progressive dilatation spontaneously (19%) or after non-surgical treatment (7%). The remaining 27 (25%) either eventually required a VP shunt (17%) or died (8%). The adverse outcome of death or requirement for a VP shunt therefore occurred in 12% of the starting population of 221 infants with IVH who survived more than 14 days.

Predictors of occurrence and outcome of PVD
Of the infants with IVH who survived more than 14 days, the occurrence of PVD and the requirement for surgical ventricular drainage were most strongly predicted by severity of IVH (table 1). PVD occurred in 4% of infants with grade 1 IVH, 12% with grade 2 IVH, 74% with grade 3 IVH and 71% with grade 4 IVH. As noted earlier, 82% of grade 3 haemorrhages were bilateral.

Compared with infants who did not develop PVD, those who did were significantly smaller, more immature, sicker in the first 12 hours of life as manifested by a higher CRIB score, and had significantly greater hypercarbia, and a greater number of infants who developed PVD required inotropic support for hypotension (table 2). However, the strongest predictor of the occurrence of PVD was severity of IVH, in particular grade 3/4. There was no significant difference between the three groups with respect to either antenatal corticosteroid treatment or hypertension during the first 48 hours of life.

Ordinal logistic regression analysis was carried in two stages to further examine the predictors of PVD, first regressing the outcome on predictors other than grade of IVH and Table 1

<table>
<thead>
<tr>
<th>Grade of IVH</th>
<th>Deaths in first 14 days</th>
<th>PVD in survivors &gt;14 days old</th>
<th>Surgery + late death</th>
<th>Surgery in survivors</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;750 g (n=75)</td>
<td>751–1500 g (n=173)</td>
<td>&lt;750 g (n=56)</td>
<td>751–1500 g (n=165)</td>
</tr>
<tr>
<td>I (n=104)</td>
<td>3/24 (12)</td>
<td>0/80 (0)</td>
<td>1/21 (5)</td>
<td>3/80 (4)</td>
</tr>
<tr>
<td>II (n=65)</td>
<td>5/21 (24)</td>
<td>1/44 (2)</td>
<td>1/16 (6)</td>
<td>6/43 (14)</td>
</tr>
<tr>
<td>III (n=45)</td>
<td>6/19 (32)</td>
<td>2/26 (8)</td>
<td>10/13 (77)</td>
<td>18/24 (73)</td>
</tr>
<tr>
<td>IV (n=34)</td>
<td>5/11 (45)</td>
<td>5/23 (22)</td>
<td>5/6 (83)</td>
<td>12/18 (66)</td>
</tr>
</tbody>
</table>

Values in parentheses are percentages.
PVD, Progressive ventricular dilatation.

Figure 1
Natural history of very low birthweight infants with posthaemorrhagic ventricular dilatation (PVD), IVH, Intraventricular haemorrhage.
then including grade of IVH. The first analysis showed that only length of gestation was a significant predictor in the logistic regression model. Further, this variable remained significant when grade of IVH was also entered (table 3). The odds ratio for grade of IVH suggests occurrence of PVD decreased by 0.85 for each week of increase in gestation. Similarly, the odds ratio for length of gestation suggests that the odds of IVH, Intraventricular haemorrhage.

<table>
<thead>
<tr>
<th>Measure</th>
<th>No ventricular dilatation</th>
<th>Non-progressive ventricular dilatation</th>
<th>Progressive ventricular dilatation</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Male</td>
<td>54.1</td>
<td>68.5</td>
<td>55.4</td>
<td>&gt; 0.15</td>
</tr>
<tr>
<td>Gestation (weeks)</td>
<td>27.9 (2.7)</td>
<td>26.3 (2.2)</td>
<td>26.2 (2.0)</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>1053 (285)</td>
<td>965 (297)</td>
<td>938 (273)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>CRIB score</td>
<td>4.6 (4.1)</td>
<td>6.0 (4.2)</td>
<td>7.1 (4.1)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>% Maximum IVH grade 3 or 4</td>
<td>0.0</td>
<td>29.6</td>
<td>80.4</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>Maximum PCO2</td>
<td>53.6 (14.0)</td>
<td>62.2 (16.3)</td>
<td>60.1 (15.6)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>% Hypertension</td>
<td>51.4</td>
<td>46.3</td>
<td>50.0</td>
<td>&gt; 0.8</td>
</tr>
<tr>
<td>% Intropic support</td>
<td>45.9</td>
<td>63.0</td>
<td>75.0</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>% Antenatal steroids</td>
<td>81.1</td>
<td>77.8</td>
<td>69.6</td>
<td>&gt; 0.20</td>
</tr>
</tbody>
</table>

Table 3 Summary of ordinal regression coefficients for significant predictors of progressive ventricular dilatation

<table>
<thead>
<tr>
<th>Measure</th>
<th>B (se)</th>
<th>p Value</th>
<th>Odds ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestation</td>
<td>-16 (0.07)</td>
<td>&lt;0.05</td>
<td>0.85</td>
<td>0.75 to 0.97</td>
</tr>
<tr>
<td>Grade of IVH</td>
<td>1.66 (0.19)</td>
<td>&lt;0.0001</td>
<td>5.27</td>
<td>3.62 to 7.63</td>
</tr>
</tbody>
</table>

CI, Confidence interval; IVH, intraventricular haemorrhage.

DISCUSSION

This cohort of VLBW infants with IVH represents the largest number of infants studied in the late 1990s to examine the incidence of PVD, outline its subsequent course and natural history, and identify predictive factors for adverse short term outcome, defined as requirement for surgical treatment for PVD or death. This sample is characterised by predominantly extremely premature, extremely low birthweight infants surviving in the late 1990s in tertiary care facilities in the United States and New Zealand. The mean (SD) gestational age of 26.8 (2.6) weeks and the mean birth weight of 950 (306) g defines a cohort of smaller, more immature infants than in the cohorts studied in the late 1980s and early 1990s.

The incidence and subsequent course of PVD, we found that 25% of all infants with IVH developed PVD. This proportion is slightly less than that previously observed.10 11 However, of the infants who did develop PVD, the course of PVD continued to be aggressive with significant mortality and morbidity. Spontaneous arrest of PVD occurred in only 21 (38%) of the 56 infants with PVD. Of the 62% of infants with PVD without spontaneous arrest—that is, persistent PVD—48% required pharmacological treatment and/or drainage of cerebrospinal fluid by serial lumbar punctures, fully 34% ultimately required surgery, and 18% died. Of the 27 infants with persistent PVD treated non-surgically, eight had arrest of their PVD and the remaining 19 required surgical intervention. An additional 21 infants (19% of PVD) had spontaneous arrest of...
PVD—that is, without intervention. Thus, overall, 52% of infants with PVD experienced spontaneous or treatment induced arrest compared with 46% in a previous study, and 34% ultimately required VP shunt treatment and 18% died compared with 31–50% and 19–20% respectively cited in previous studies.13–17 The optimal treatment strategy for posthaemorrhagic ventricular dilatation is not known, but our data reflect differing management plans. Recent studies, published after the period of observation in this study, indicate that neither diuretic treatment nor serial lumbar punctures are beneficial in the management of posthaemorrhagic ventricular dilatation.14–16

Concerning predictive factors for adverse short term outcome, including surgical treatment for PVD and death, it is important to note that the indications for surgical treatment of infants with PVD in all the units involved in our study have not changed in recent years. The indications for surgical intervention by placement of either a ventricular reservoir or VP shunt are persistent PVD with signs of increased intracranial pressure and failure to respond to other treatment, including serial lumbar punctures or medical treatment or both. The high incidence of VP shunt insertion in our cohort appears to be related to increased numbers of extremely low birthweight infants (<1000 g) surviving with severe (grades 3/4) IVH and thereby an increased risk of PVD. Thus, as in previous studies, the risk of adverse outcome, defined in the short term as death or PVD necessitating surgical treatment by VP shunt, was most strongly related to the severity of the initial IVH, with some relation also to earlier gestation.11–20

Although other risk factors, including low birth weight, illness severity as quantified by CRIB scores, hypotension necessitating inotropic support, or worse respiratory illness manifested as elevated Pco2, were found to be associated with an increased risk of PVD, unlike previous studies21 these variables did not predict the requirement for VP shunt when grade of IVH was taken into account. This suggests that these other risk factors indicate infants at risk of severe IVH. Only grade of IVH (p < 0.0001) was significantly related to the likelihood of surgical intervention. Although antenatal administration of corticosteroids has been shown to lead to reduced mortality, respiratory distress syndrome, and IVH in preterm infants,22–23 in our cohort, there was no significant effect of antenatal steroids on the occurrence of PVD or the need for VP shunt insertion for PVD. This finding may reflect the high background use of antenatal corticosteroids, which were administered to 78% of mothers in our cohort.

Our study emphasises in this population of extremely preterm infants characteristic of the late 1990s that severe IVH is the major predictor of adverse short term outcome, defined as death or the subsequent need for surgical intervention for PVD. Although the overall incidence of IVH in this vulnerable population in modern day neonatal intensive care facilities has not changed appreciably, the severity of the lesion has increased and thereby so has the risk of adverse short term outcome. Conversely, it is rare for an infant with grade 1 or 2 IVH to develop PVD that requires surgical intervention. These data can be useful to the clinician in the anticipatory management of very small premature infants. Future research to find strategies for the prevention of severe IVH will have the greatest impact on prevention of PVD and the requirement for surgical intervention.

Authors’ affiliations
B P Murphy, Division of Newborn Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
T E Inder, J J Volpe, Department of Neurology, Children’s Hospital Boston, Harvard Medical School, Boston, USA
V Rooks, G A Taylor, Department of Radiology, Children’s Hospital Boston
N J Anderson, Department of Radiology, Christchurch Hospital, University of Otago, New Zealand
N Magriddle, Department of Paediatrics, Christchurch Hospital
L J Horwood, Christchurch School of Medicine, Christchurch, New Zealand

REFERENCES